Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review
Executive SummaryThe latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.